Chiesi
Also known as: CHIESI | Chiesi España | Chiesi Farmaceutici | Chiesi Farmaceutici S.p.A. | CHIESI FARMACEUTICI SPA | Chiesi GmbH | Chiesi Pharmaceuticals | Chiesi Slovenija, d.o.o. | Chiesi UK | Chiesi USA | Chiesi USA, Inc. | CHIESI USA INC | Innovair | Medical Department; Chiesi Farmaceutici S.p.A (Italy)
Highest phase reached
Phase 4
First clinical trial
Aug 1, 2002First marketed drug
Dec 21, 1988First NDA
Oct 30, 1996Last known activity
May 14, 2026
Timeline
1930s
- Jan 1, 1935
Chiesi— Founded
1990s
- Dec 9, 1996
zileuton— NDA Organization
2000s
- Aug 1, 2008
clevidipine— Marketing Organization
- Aug 1, 2008
clevidipine— NDA Secondary Org
2010s
- Jan 1, 2013
Zymenex— Acquired
- Jan 1, 2014
Cornerstone Therapeutics— Acquired
- Nov 21, 2016
Atopix Therapeutics, Ltd.— Acquired
2020s
- Jan 9, 2023
Amryt Research Limited— Acquired
- Oct 6, 2025
Arbor Biotechnologies— Acquired
Drugs by trial phase (111 distinct, 273 trials)
Phase 4 (14 own, 7 via acquisition)
Phase 3 (18 own, 16 via acquisition)
Phase 2 (19 own, 25 via acquisition)
Phase 1 (7 own, 4 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Coronary Syndrome
- Acute Lung Injury
- alpha-Mannosidosis
- Alzheimer Disease
- Asthma
- Bronchiectasis
- Bronchopulmonary Dysplasia
- Cognitive Dysfunction
- Croup
- Cystic Fibrosis
- Emphysema
- Exocrine Pancreatic Insufficiency
- Fibrosis
- Foot Ulcer
- Heart Arrest
- Heart Diseases
- Hemophilia A
- Hemophilia B
- Hyperlipoproteinemia Type I
- Hyperplasia
- Hypertension
- Hypoplastic Left Heart Syndrome
- Idiopathic Pulmonary Fibrosis
- Infant, Premature, Diseases
- Infarction
- Kidney Failure, Chronic
- Lung Diseases
- Lung Diseases, Obstructive
- Mannosidase Deficiency Diseases
- Meningitis
- Metabolic Syndrome
- Myocardial Infarction
- Neonatal Abstinence Syndrome
- Obesity
- Osteoporosis
- Osteoporosis, Postmenopausal
- Out-of-Hospital Cardiac Arrest
- Pneumonia
- Pneumonia, Ventilator-Associated
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Eosinophilia
- Pulmonary Fibrosis
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Sepsis
- Sinusitis
- ST Elevation Myocardial Infarction
- Substance Withdrawal Syndrome
- Syndrome
- Thrombosis
- Tissue Adhesions
- Toxemia
- Ulcer
Marketed drugs (18)
Subsidiaries (5 direct, 12 total across the full acquisition tree)
Recent trials (50)
- NCT04552691CollaboratorN/A—
- NCT04959240Lead sponsorN/A—
- NCT04552691Study directorN/A—
- NCT07181382CollaboratorPhase 3Dec 31, 2025
- NCT07301736Lead sponsorPhase 2Dec 15, 2025
- NCT07163182Lead sponsorPhase 1Sep 15, 2025
- NCT06917690Lead sponsorPhase 3Apr 18, 2025
- NCT06900816Lead sponsorPhase 2Mar 28, 2025
- NCT06892756Lead sponsorPhase 1Mar 18, 2025
- NCT06746064Lead sponsorPhase 1Jan 9, 2025
- NCT06328608Lead sponsorPhase 2/Phase 3Oct 31, 2024
- NCT06395610Lead sponsorPhase 1Mar 28, 2024
- NCT06166056Lead sponsorPhase 1/Phase 2Nov 29, 2023
- NCT06029595Lead sponsorPhase 2Nov 28, 2023
- NCT06264674Lead sponsorPhase 3Nov 27, 2023
Details
- Founded
- Parma, IT Jan 1, 1935
- First NDA
- Oct 30, 1996
- Last known activity
- May 14, 2026
Designations held
- Orphan drug
- Fast track
- Priority review